RB
RB0.F REGENXBIO Inc
- Market cap
- EUR 472M
- P/E
- -
- P/B
- 3.44x
- ROE
- -97.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RB0.F undervalued?
Graham numberThe Graham number of REGENXBIO Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
REGENXBIO Inc fundamental analysis
No fundamental analysis for REGENXBIO Inc yet.
REGENXBIO Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About REGENXBIO Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-…
Full company profileREGENXBIO Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
REGENXBIO Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.59M | 10.4M | 219M | 35.2M | 155M | 470M | 113M | 90.2M | 83.3M | 170M | 165M |
| Gross Profit | 3.63M | 8.68M | 209M | 27.0M | 119M | 419M | 58.2M | 53.0M | 49.8M | 150M | 147M |
| Operating Income | -65.3M | -75.9M | 88.1M | -149M | -119M | 160M | -263M | -268M | -231M | -161M | -170M |
| EBITDA | - | -73.2M | 92.1M | -142M | -96.8M | 177M | -257M | -239M | -198M | -133M | -97.3M |
| Net Income | -63.0M | -73.2M | 99.9M | -94.7M | -111M | 128M | -280M | -263M | -227M | -194M | -144M |
| EPS | - | -2.34 | 2.77 | -2.56 | -2.97 | 2.98 | -6.47 | -5.98 | -4.58 | -3.81 | -2.18 |
| Balance Sheet | |||||||||||
| Total Assets | 173M | 199M | 544M | 498M | 708M | 1.11B | 833M | 574M | 466M | 453M | 466M |
| Total Liabilities | 11.0M | 15.6M | 35.0M | 47.7M | 330M | 350M | 317M | 262M | 206M | 350M | 318M |
| Shareholders' Equity | 162M | 183M | 509M | 450M | 378M | 764M | 516M | 312M | 260M | 103M | 148M |
| Cash & Short-term Investments | 24.8M | 46.7M | 75.6M | 69.5M | 338M | 345M | 97.0M | 34.5M | 57.5M | 34.5M | 95.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -48.6M | -58.0M | 105M | -108M | -54.1M | 219M | -207M | -218M | -173M | -124M | -133M |
| Capital Expenditure | 8.15M | 7.16M | 13.3M | 11.7M | 26.9M | 84.2M | 30.7M | 9.96M | 2.44M | 2.41M | 2.92M |
| Free Cash Flow | - | -65.2M | 91.4M | -119M | -80.9M | 135M | -238M | -228M | -176M | -126M | -136M |
| Ratios | |||||||||||
| ROE | -38.9% | -40.0% | 19.6% | -21.0% | -29.5% | 16.7% | -54.3% | -84.5% | -87.5% | -188.7% | -97.3% |
| ROA | -36.5% | -36.8% | 18.4% | -19.0% | -15.7% | 11.5% | -33.6% | -45.9% | -48.7% | -42.8% | -30.9% |
| Net Profit Margin | -1,372.1% | -704.0% | 45.7% | -268.9% | -72.0% | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% | -87.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
REGENXBIO Inc dividends
REGENXBIO Inc has not paid dividends in the last 9 fiscal years.
Who owns REGENXBIO Inc
- Insiders 6.50%
- Institutions 68.73%
- Public & others 24.77%
- Shares outstanding 66.1M
- Free float 57.3M
REGENXBIO Inc company profile
- Company name
- REGENXBIO Inc
- Ticker
- RB0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 371
- Fiscal year end
- December
- Address
- 9804 Medical Center Drive, Rockville, MD, United States, 20850
- Phone
- 240 552 8181
- Website
- regenxbio.com
About REGENXBIO Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
REGENXBIO Inc management
9- Mr. Curran M. Simpson M.S.President, CEO & Director · born 1962
- Mr. Patrick J. Christmas II, J.D.Executive VP and Chief Strategy & Legal Officer · born 1971
- Dr. Stephen Pakola M.D.Executive VP & Chief Medical Officer · born 1969
- Mr. Mitchell Chan M.B.A.Executive VP & CFO · born 1981
- Mr. Craig MalzahnExecutive VP of Product Development & CTO · born 1973
- Dr. Olivier Danos Ph.D.Executive VP & Chief Scientific Officer · born 1958
- Ms. Marianne KreinerHead of People
- Dr. Ram Palanki Pharm.D.Executive VP & Chief Commercial Officer · born 1976
- Dr. Jahannaz Dastgir D.O.Clinical Development Lead